Also found in: Dictionary.
Related to Levoxyl: hypothyroidism, Levothyroxine, Cialis, Synthroid, levothyroxine sodium
levothyroxine sodium (L-thyroxine, T4)
Eltroxin (CA) (UK), Euthyrox (CA), Evotrox (UK), Levo-T, Levolet, Levothroid, Levoxyl, Nu-Thyro (CA), Soloxine, Synthroid, Unithroid
Pharmacologic class: Synthetic thyroxine hormone
Therapeutic class: Thyroid hormone replacement
Pregnancy risk category A
FDA Box Warning
• Drug shouldn't be used alone or with other agents to treat obesity or weight loss. In euthyroid patients, doses within range of daily hormonal requirements are ineffective for weight loss. Larger doses may cause serious or life-threatening toxicity, particularly when given with sympathomimetic amines (such as those used for anorectic effects).
Synthetic form of thyroxine that replaces endogenous thyroxine, increasing thyroid hormone levels. Thyroid hormones help regulate cell growth and differentiation and increase metabolism of lipids, protein, and carbohydrates.
Powder for injection: 200 mcg/vial in 6- and 10-ml vials, 500 mcg/vial in 6- and 10-ml vials
Tablets: 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, 300 mcg
⊘Indications and dosages
➣ Hypothyroidism; treatment or prevention of euthyroid goiter
Adults: For healthy adults younger than age 50 and those over age 50 who have recently been treated or undergone short-term therapy, start at full replacement dosage of 1.7 mcg/kg P.O. daily, given 30 minutes to 1 hour before breakfast. For patients older than age 50 or younger than age 50 with heart disease, 25 to 50 mcg P.O. daily, increased q 4 to 6 weeks. In severe hypothyroidism, initial dosage is 12.5 to 25 mcg P.O. daily, adjusted by 25 mcg daily q 2 to 4 weeks. For patients who can't tolerate oral doses, adjust I.M. or I.V. dosage to roughly half of oral dosage.
➣ Congenital hypothyroidism
Children older than age 12 who have completed puberty and growth: 1.7 mcg/kg P.O. daily
Children older than age 12 who have not completed puberty and growth: Up to 150 mcg or 2 to 3 mcg/kg P.O. daily
Children ages 6 to 12: 4 to 5 mcg/kg P.O. daily
Children ages 1 to 5: 5 to 6 mcg/kg P.O. daily
Infants ages 6 to 12 months: 6 to 8 mcg/kg P.O. daily
Pharmacologic: thyroid preparations
- Promote gluconeogenesis,
- Increase utilization and mobilization of glycogen stores,
- Stimulate protein synthesis,
- Promote cell growth and differentiation,
- Aid in the development of the brain and CNS.
|Levothyroxine PO||unknown||1–3 wk||1–3 wk|
|Levothyroxine IV||6–8 hr||24 hr||unknown|
Adverse Reactions/Side EffectsUsually only seen when excessive doses cause iatrogenic hyperthyroidism
Central nervous system
- angina pectoris
- abdominal cramps
- menstrual irregularities
- heat intolerance
- weight loss
- accelerated bone maturation in children
Drug-Drug interactionBile acid sequestrants and orlistat ↓ absorption of orally administered thyroid preparations.May ↑ the effects of warfarin.May ↑ requirement for insulin or oral hypoglycemic agents in diabetics.Concurrent estrogen therapy may ↑ thyroid replacement requirements.↑ cardiovascular effects with adrenergics (sympathomimetics).Foods or supplements containing calcium, iron, magnesium, or zinc may bind levothyroxine and prevent complete absorption.
Availability (generic available)
- Assess apical pulse and BP prior to and periodically during therapy. Assess for tachyarrhythmias and chest pain.
- Children: Monitor height, weight, and psychomotor development.
- Lab Test Considerations: Monitor thyroid function studies prior to and during therapy. Monitor thyroid-stimulating hormone serum levels in adults 8–12 wks after changing from one brand to another.
Overdose is manifested as hyperthyroidism (tachycardia, chest pain, nervousness, insomnia, diaphoresis, tremors, weight loss). Usual treatment is to withhold dose for 2–6 days then resume at a lower dose. Acute overdose is treated by induction of emesis or gastric lavage, followed by activated charcoal. Sympathetic overstimulation may be controlled by antiadrenergic drugs (beta blockers), such as propranolol. Oxygen and supportive measures to control symptoms are also used.
- Monitor blood and urine glucose in diabetic patients. Insulin or oral hypoglycemic dose may need to be increased.
Potential Nursing DiagnosesDeficient knowledge, related to medication regimen (Patient/Family Teaching)
- Do not confuse levothyroxine with lamotrigine or Lanoxin (digoxin).
- Administer as a single dose with a full glass of water, preferably before breakfast to prevent insomnia.
- Initial dose is low, especially in geriatric and cardiac patients. Dose is increased gradually, based on thyroid function tests.
- For patients with difficulty swallowing, tablets can be crushed and placed in 5–10 mL of water and administered immediately via dropper or spoon; do not store suspension.
- Reconstitute the 200-mcg and 500-mcg vials with 2 or 5 mL, respectively, of 0.9% NaCl without preservatives (diluent usually provided). Concentration: 100 mcg/mL. Shake well to dissolve completely. Administer solution immediately after preparation; discard unused portion.
- Rate: Administer at a rate of 100 mcg over 1 min. Do not add to IV infusions; may be administered through Y-tubing.
- Y-Site Incompatibility: Do not admix with other IV solutions.
- Instruct patient to take medication as directed at the same time each day. Take missed doses as soon as remembered unless almost time for next dose. If more than 2–3 doses are missed, notify health care professional. Do not discontinue without consulting health care professional.
- Explain to patient that medication does not cure hypothyroidism; it provides a thyroid hormone supplement. Therapy is lifelong.
- Advise patient to notify health care professional if headache, nervousness, diarrhea, excessive sweating, heat intolerance, chest pain, increased pulse rate, palpitations, weight loss >2 lb/wk, or any unusual symptoms occur.
- Caution patient to avoid taking other medications concurrently with thyroid preparations unless instructed by health care professional.
- Instruct patient to inform health care professionals of thyroid therapy.
- Emphasize importance of follow-up exams to monitor effectiveness of therapy. Thyroid function tests are performed at least yearly.
- Pediatric: Discuss with parents the need for routine follow-up studies to ensure correct development. Inform patient that partial hair loss may be experienced by children on thyroid therapy. This is usually temporary.
- Resolution of symptoms of hypothyroidism and normalization of hormone levels.